$2.025
-0.186 (-9.19%)收盤時
IPSC 資訊
IPSC 事件
Century Therapeutics Advances CNTY-813 Development Progress
"We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Chief Executive Officer of Century Therapeutics. "With CNTY-813, our preclinical data at ADA 2026 continue to support its potential as a functional T1D cure, and we have established our Phase 1 manufacturing process, demonstrating consistent product quality across independent batches. Our recent pre-IND meeting with the FDA builds on that progress yielding alignment with the FDA on our nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design, keeping CNTY-813's IND submission on track for the fourth quarter of 2026. In addition, CNTY-308 remains on track to enter the clinic in 2026."
Century Therapeutics Advances CNTY-813 Development Progress
"We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion engineering with a scalable iPSC platform," said Brent Pfeiffenberger, Chief Executive Officer of Century Therapeutics. "In a relatively short time since initiating this program, we have advanced CNTY-813 into IND-enabling studies on a timeline we believe is highly competitive with leading efforts in the field. With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated in the second half of 2027, our focus is clear: to deliver a differentiated, patient-centric, potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY-308."
Century Therapeutics Reports FY25 Revenue of $109.164M
Reports FY25 revenue $109.164M, consensus $109.17M. "Century entered 2026 with strong momentum, fueled by the successful completion of our $135 million private placement and continued focus on advancing our prioritized programs closer to patients living with significant unmet medical need," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. "We are moving fast and executing with precision on CNTY-813, our top priority and a program we believe has the potential to functionally cure type 1 diabetes. Recent achievements, including compelling preclinical results combined with constructive interactions with the FDA, strengthen our confidence in the clinical path ahead. We plan to submit an IND as early as the fourth quarter of this year and anticipate initial clinical data in the second half of 2027. We are energized by the progress across our pipeline, confident in the road ahead, and focused on advancing our most promising programs into the clinic."
Century Therapeutics Completes $135M Private Placement Financing
Century Therapeutics has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135M to the Company, before placement agent fees and offering expenses. The financing is being led by new investor TCGX, and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, and the T1D Fund. The private placement is expected to close on January 9, subject to customary closing conditions. Pursuant to the terms of the securities purchase agreement, Century Therapeutics will issue approximately 117,391,299 shares of common stock and accompanying warrants to purchase 58,695,648 shares of common stock in the private placement at a purchase price of $1.15 per share and accompanying warrant to purchase 0.5 shares of common stock and at a purchase price of $1.1499 per pre-funded warrant and accompanying warrant to purchase 0.5 shares of common stock. The pre-funded warrants will be exercisable immediately at an exercise price of $0.0001 per share and will not expire until exercised in full. The warrants to purchase common stock will be exercisable immediately upon issuance at an exercise price of $2.60 per share or $2.599 per pre-funded warrant and will expire upon the earlier of 30 days after the public announcement of initial Phase 1 clinical data for CNTY-813 and the third anniversary of the closing of the private placement. Full exercise of the warrants would provide an additional approximately $153M in gross proceeds to the Company. Leerink Partners, TD Cowen and Mizuho acted as the placement agents for the private placement.
Century Therapeutics Appoints New Board Members
Century Therapeutics announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。